CY1123818T1 - Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο - Google Patents

Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο

Info

Publication number
CY1123818T1
CY1123818T1 CY20211100128T CY211100128T CY1123818T1 CY 1123818 T1 CY1123818 T1 CY 1123818T1 CY 20211100128 T CY20211100128 T CY 20211100128T CY 211100128 T CY211100128 T CY 211100128T CY 1123818 T1 CY1123818 T1 CY 1123818T1
Authority
CY
Cyprus
Prior art keywords
syd985
treatment
deficiency
cancer patients
patients
Prior art date
Application number
CY20211100128T
Other languages
English (en)
Inventor
Gerrit Voortman
Norbert Peter KOPER
Original Assignee
Byondis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis B.V. filed Critical Byondis B.V.
Publication of CY1123818T1 publication Critical patent/CY1123818T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στο προϊόν σύζευξης αντισώματος-φαρμάκου (ADC) τραστουζουμάμπη vc-seco-DUBA (SYD985) που περιέχει δουοκαρμυκίνη για χρήση στη θεραπεία δυσίατων με τραστουζουμάμπη εμτανσίνη (T-DM1) HER2 IHC 3+ ή HER2 IHC 2 + / FISH θετικών ασθενών με καρκίνο, ιδιαίτερα ασθενών με δυσίατο με T-DM1 καρκίνο του μαστού.
CY20211100128T 2015-09-22 2021-02-16 Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο CY1123818T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15186258 2015-09-22
EP16158710 2016-03-04
EP16169699 2016-05-13
PCT/EP2016/072464 WO2017050846A1 (en) 2015-09-22 2016-09-21 Syd985 treatment of t-dm1 refractory cancer patients

Publications (1)

Publication Number Publication Date
CY1123818T1 true CY1123818T1 (el) 2022-05-27

Family

ID=57068063

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100128T CY1123818T1 (el) 2015-09-22 2021-02-16 Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο

Country Status (21)

Country Link
US (1) US10821191B2 (el)
EP (1) EP3352857B1 (el)
JP (1) JP6591665B2 (el)
KR (1) KR20180052761A (el)
CN (1) CN108025190A (el)
AU (1) AU2016328461B2 (el)
BR (1) BR112018005494A2 (el)
CA (1) CA2996600A1 (el)
CL (1) CL2018000726A1 (el)
CY (1) CY1123818T1 (el)
DK (1) DK3352857T3 (el)
ES (1) ES2854298T3 (el)
HR (1) HRP20210418T1 (el)
HU (1) HUE053614T2 (el)
LT (1) LT3352857T (el)
MX (1) MX2018003459A (el)
MY (1) MY194488A (el)
PL (1) PL3352857T3 (el)
RU (1) RU2728101C2 (el)
WO (1) WO2017050846A1 (el)
ZA (1) ZA201801022B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386867A1 (en) * 2018-11-09 2021-12-16 Byondis B.V. Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
CN114845738A (zh) * 2019-12-20 2022-08-02 辉瑞大药厂 使用位点特异性her2抗体-药物缀合物的治疗
WO2023068325A1 (ja) * 2021-10-20 2023-04-27 国立研究開発法人産業技術総合研究所 抗ガン剤、抗ガン剤のプロドラッグ、体外でガン細胞を死滅させる方法、ガンの治療方法、及びガンの治療装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2450755T3 (es) * 2007-10-19 2014-03-25 Genentech, Inc. Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco
DK3108886T3 (da) * 2010-04-21 2020-08-10 Syntarga Bv Konjugater af CC-1065-analoger og bifunktionelle linkere
EP3069735B1 (en) 2014-01-10 2018-03-14 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in the treatment of bladder cancer

Also Published As

Publication number Publication date
WO2017050846A1 (en) 2017-03-30
MY194488A (en) 2022-11-30
AU2016328461B2 (en) 2021-04-08
RU2018114457A (ru) 2019-10-24
EP3352857B1 (en) 2021-01-13
LT3352857T (lt) 2021-02-25
CL2018000726A1 (es) 2018-06-01
AU2016328461A1 (en) 2018-02-22
RU2018114457A3 (el) 2020-01-31
ZA201801022B (en) 2021-05-26
EP3352857A1 (en) 2018-08-01
BR112018005494A2 (pt) 2018-10-09
HRP20210418T1 (hr) 2021-04-30
US10821191B2 (en) 2020-11-03
HUE053614T2 (hu) 2021-07-28
CN108025190A (zh) 2018-05-11
JP2018527402A (ja) 2018-09-20
PL3352857T3 (pl) 2021-08-02
JP6591665B2 (ja) 2019-10-16
CA2996600A1 (en) 2017-03-30
DK3352857T3 (da) 2021-03-01
US20180280533A1 (en) 2018-10-04
MX2018003459A (es) 2018-06-06
ES2854298T3 (es) 2021-09-21
KR20180052761A (ko) 2018-05-18
RU2728101C2 (ru) 2020-07-28

Similar Documents

Publication Publication Date Title
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
CY1123818T1 (el) Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο
ZA201905488B (en) Tigit- and light-based chimeric proteins
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
BR112019010020A2 (pt) compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
CY1117712T1 (el) Adcs δουοκαρμυκινης για χρηση στη θεραπεια ενδομητριου καρκινου
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MY178160A (en) Anti-egfrviii antibodies and uses thereof
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2018005232A (es) Anticuerpos anti-cd3 novedosos y sus usos.
MX2022000450A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12016502042A1 (en) Drug delivery conjugates for treating resistant cancer and for use in combination therapy
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
MX2023006787A (es) Trastuzumab emtansina para usarse en el tratamiento de cancer de mama residual.